Oncimmune's study data to be featured at prestigious cancer research conference

The presentation will be the first time that the clinical utility of autoantibodies has been presented at the American Society of Clinical Oncology conference

Oncimmune -

Oncimmune Holdings PLC (LON:ONC) has said findings from one of its studies are to be featured at a prestigious international cancer research conference this month.

The immunodiagnostics group announced that its data from profiling tumour associated antibodies in melanoma patients receiving immune checkpoint inhibitors has been selected as a featured presentation at the upcoming American Society of Clinical Oncology 2020 – ASCO for short – Virtual Scientific Programme, which will take place from May 29 to May 31.

The featured presentation will review data assessing samples from patients receiving either Pembrolizumab, Ipilimumab, Nivolumab monotherapy, or combination therapy of Ipilimumab and Nivolumab, which have been analysed on Oncimmune's proprietary biomarker discovery engine, SeroTag.

The data identified that autoantibodies have a role in predicting clinical outcomes or immune-related adverse events (irAEs).

The presentation will be the first time that the clinical utility of autoantibodies has been presented at this prestigious international cancer research conference.

“This study provides further evidence that autoantibodies play an important role in identifying patients likely to suffer irAEs in response to cancer immunotherapy, this time in patients suffering from melanoma. Importantly, the study also reinforces the evidence base underpinning the utility of tumour-related antibodies in predicting clinical responses to commonly used first-line treatment immunotherapies,” Adam Hill, the chief executive officer of Oncimmune said in a statement.

"Oncimmune is at the forefront in understanding the utility of autoantibodies in a clinical setting. This exciting study demonstrates the strides we have made in unlocking the potential of our autoantibody platform to improve patient outcomes," he added.

Quick facts: Oncimmune

Price: 175 GBX

Market: AIM
Market Cap: £111.2 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...


Market report: FTSE falls as UK unemployment rises to a three-year high

FTSE 100 saw a subdued start after summer unemployment numbers hit a three-year high. London’s leading index dropped 30 points to 5,970 in early dealings. The UK’s unemployment rate rose to 4.5% between June and August while redundancies were at their highest level since 2009. Numbers are...

1 week ago

2 min read